

**Reference:** FOI.ICB-2627/038

**Subject:** Local diagnostic and care pathways for Liver diseases: MASLD and MASH

*I can confirm that the ICB does hold some of the information requested; please see responses below:*

QUESTION	RESPONSE
<p>1. Please could you tell me, within any local Liver Disease pathway, does the ICB currently have a dedicated strategy, policy or work programme relating to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)?</p> <p>If so, please confirm whether this is (a) in place, (b) in development, or (c) not in place, and provide copies of any relevant documents</p>	<p>There is currently no specific system-wide programme of work or dedicated policy or strategy in the ICB for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH).</p> <p>Partners within the BNSSG (Bristol, North Somerset and South Gloucestershire) system are involved in the 'Alright My Liver' NHS pilot.</p>
<p>2. Please could you tell me, is liver disease (including Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis) referenced as a priority condition in the ICB's integrated care strategy or joint forward plan?</p> <p>If so, please provide the relevant excerpts</p>	<p>Liver disease is recognised in our Joint Forward Plan. Available here <a href="#">Bristol, North Somerset and South Gloucestershire Integrated Care System Joint Forward Plan 2025 to 2030</a> – see page 6, where it lists a number of areas of work to be developed including 'Chronic liver disease'.</p> <p>There is reference to Metabolic Syndrome and fatty liver disease in the appendices of our Healthier Together 2040 commitments <a href="#">Healthier Together 2040 - BNSSG Healthier Together</a> in the publication <a href="#">Understanding working-age adults affected by multiple long-term conditions and those at future risk - BNSSG Healthier Together</a> page 47.</p>

<p>3. Please could you tell me, does the ICB have a locally agreed primary care pathway, protocol or clinical guideline for the assessment and management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)?</p> <p>Please confirm whether this is (a) in place, (b) in development, or (c) not in place, and if in place, please provide a copy of the most recent version</p>	<p>Please see <a href="#">Liver disease (Remedy BNSSG ICB)</a> for all information on referral pathways, protocols, clinical guidelines and additional resources.</p> <p>There is a specific link in the page detailing the pathway for Metabolic Associated Steatohepatitis Liver Disease (MASLD).</p>
<p>4. Please could you tell me, do any Community Diagnostic Centres (CDCs) within the ICB offer liver fibrosis diagnostics?</p> <p>Please confirm which CDCs provide these services and specify the tests available, including transient elastography (FibroScan), the FIB-4 index, and the enhanced liver fibrosis (ELF) blood test</p>	<p>The CDCs in BNSSG do not offer liver fibrosis diagnostics. Access to diagnostics in the BNSSG system (including ultrasound, FibroScan as well as detail on NILS, FIB-4, ELF etc) is described here <a href="#">Liver disease (Remedy BNSSG ICB)</a></p>
<p>5. Please could you tell me, has the ICB carried out any assessment, review or analysis of specialist hepatology workforce capacity and demand within the last two years?</p> <p>Please confirm whether this is (a) completed, (b) in progress, or (c) not undertaken, and if completed, please provide copies of any reports, briefing papers, or presentations that set out the findings</p>	<p>The ICB has not carried out a review specifically of the hepatology workforce in the last 2 years. Please contact the Trusts, hepatology services directly for information related to their demand, capacity modelling.</p> <p>North Bristol NHS Trust (NBT): <a href="https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information">https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information</a></p> <p>University Hospitals Bristol and Weston NHS Foundation Trust (UHBW): <a href="https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests">https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests</a></p>

6. Please could you tell me, has the ICB made any plans, business cases or budget provisions in anticipation of the forthcoming NICE guideline 'Metabolic dysfunction-associated steatotic liver disease (MASLD)' (GID-NG10434)?

Please confirm whether planning is (a) in place, (b) in development, or (c) not yet undertaken, and if in place, please provide copies of any related planning documents, meeting papers, or financial schedules.

Not at this time.

***The information provided in this response is accurate as of 12 May 2026 and has been approved for release by Caroline Dawe, Deputy Director of Performance and Delivery, Acute and Integrated Care, MHLDA and EPRR for NHS Bristol, North Somerset and South Gloucestershire ICB.***